CRSP John Greene buys $314K worth of shares
Mar 27, 2025, 10:32 AM
0.00%
What does CRSP do
CRISPR Therapeutics AG, headquartered in Zug, develops gene-based medicines for serious diseases using its CRISPR/Cas9 platform and went public on October 19, 2016. The company focuses on gene editing to treat genetically-defined diseases and enhance cellular therapies.
John Greene bought 7,000 shares of CRSP on 26 February at $44.85 per share, worth a total of $314K. They now own 7,000 CRSP shares.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.